Should we take into account ESBLs in empirical antibiotic treatment? - Wikidata - awgldk - TriplyDB

Should we take into account ESBLs in empirical antibiotic treatment?

Should we take into account ESBLs in empirical antibiotic treatment?

http://www.wikidata.org/entity/Q40492513

about

Factors associated with bacteraemia due to multidrug-resistant organisms among bacteraemic patients with multidrug-resistant organism carriage: a case control study

P2860

Erratum to: Should we take into account ESBLs in empirical antibiotic treatment?

P921

Q57064560-D868B573-37E7-43DE-A0AE-DA17D253DDEC

P2860

Q45259340-CAECDF56-B089-4488-A2FF-6FBEE7D59AA6

P921

Should we take into account ESBLs in empirical antibiotic treatment?

http://www.wikidata.org/entity/Q40492513

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Should we take into account ESBLs in empirical antibiotic treatment?

@en

type

label

Should we take into account ESBLs in empirical antibiotic treatment?

@en

prefLabel

Should we take into account ESBLs in empirical antibiotic treatment?

@en

P1433

Q40492513-ADA39467-346E-43F9-BB8F-6CCC06F323A4

P1476

Q40492513-3889DD0A-DD87-4A94-A149-E966A409D0DF

P2093

Q40492513-02AE17F7-CD68-4FF4-BF8B-2ED0D2B30D37

Q40492513-519E3514-847D-4B89-8DD7-8D2B6E6DDFA1

P2507

Q40492513-46152752-8962-4632-BEC6-77617F169FB5

P2860

Q40492513-31BC759E-04D2-4EB1-847C-9A2AB348DEFD

Q40492513-46F2D677-D42F-4811-B820-5F7CD44FCBA4

Q40492513-746FAC2F-DBCF-48DD-99FD-00163ADF6913

Q40492513-785C8B7B-47E4-4591-8AF4-2F6F41F19C8A

Q40492513-79359AB6-2CAF-4DD3-9E9D-71397EB995AB

Q40492513-81F4A9DA-7D03-447F-A677-E93AF5078629

Q40492513-94215536-BD16-42F2-BEBF-F8E7F32A6036

Q40492513-A06CBCE9-E0D1-430A-A471-936EF34DE45F

Q40492513-AD9C7742-284E-4A88-ABA4-CED94C79E614

Q40492513-B523D0C6-AFE0-4D16-AA6D-8F642DF9FC13

P2888

Q40492513-2BE1379C-2AE0-403F-8EBD-03A9B640A56F

P304

Q40492513-7E17E753-89EE-4784-BDDE-55DA84043B79

P31

Q40492513-99A8A688-A3A0-452E-8ECE-734BF8920841

P356

Q40492513-02A01BA7-03FD-4E9C-8FE1-412712B0C835

P433

Q40492513-E02D0971-2510-4D8A-8C59-78A029D84C66

P478

Q40492513-D4A06296-C3A6-4963-B2F3-BE7EB1EDF78D

P50

Q40492513-76357B13-F796-44DA-8436-3B730DE583A4

Q40492513-F86EF2B6-C4CE-40DC-ADB6-9043B7E29F9F

P577

Q40492513-B8C763D0-7AFA-4D23-B801-310321CAC697

P698

Q40492513-718369F7-968B-4DAF-AFE9-EAB041F5ADA4

P356

S00134-016-4599-6

P1433

Intensive Care Medicine

P1476

Should we take into account ESBLs in empirical antibiotic treatment?

@en

P2093

Bassetti Matteo

http://www.w3.org/2001/XMLSchema#string

Jesús Rodríguez Baño

http://www.w3.org/2001/XMLSchema#string

P2507

Erratum to: Should we take into account ESBLs in empirical antibiotic treatment?

P2860

Current trends in culture-based and molecular detection of extended-spectrum-β-lactamase-harboring and carbapenem-resistant Enterobacteriaceae

Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission.

The new beta-lactamases.

Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome

Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.

A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae

A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011.

Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology.

Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?

A Clinical Decision Tree to Predict Whether a Bacteremic Patient Is Infected With an Extended-Spectrum β-Lactamase-Producing Organism.

P2888

s00134-016-4599-6

P304

2059-2062

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00134-016-4599-6

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P50

Jesús Rodríguez-Baño

Matteo Bassetti

P577

2016-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27770171

http://www.w3.org/2001/XMLSchema#string